Stifel Reiterates Buy Rating on MBX Biosciences Inc (MBX), PT $40, 'MBX has comfortable runway into mid-2027, well past the key AVAIL readout'
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating and $40.00 price target on MBX Biosciences Inc (NASDAQ: MBX)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
